The global biotech licensing market hit a record $137 billion in 2025, and 2026 is on track to be even larger. Out‑licensing deals doubled year‑on‑year, average deal size rose 76%, and upfront payments doubled—driven by patent expiries, thin R&D pipelines, and a powerful shift in where innovation is now coming from: China.
China Overtakes the U.S. as Licensing Powerhouse
China has now overtaken the United States in clinical trial volume and is rapidly becoming the world’s top source of licenseable assets. Chinese biotechs are running more trials, generating strong data, and negotiating deals from a position of strength. Many of the biggest 2025–26 licensing deals feature innovative oncology, metabolic, and rare disease candidates originating from China, with global giants paying large upfronts and milestones to access them.
Why China Is So Attractive
- High‑quality, fast‑tracked trials: China runs large, well‑designed studies efficiently, often at lower cost and with quicker patient recruitment.
- Strong scientific base: Local companies and universities are investing heavily in AI‑driven drug discovery, antibody platforms, and cell therapies.
- Favorable IP and data environment: Local policies and strong data resources make AI‑driven discovery and licensing more attractive.
Strategic Impact for 2026
- Global pharma is increasingly depending on China‑sourced assets to fill patent‑gap voids.
- Chinese biotechs are gaining higher upfront payments and more balanced deal structures—shifting power from Big Pharma to China‑born innovation.
- Licensing deals now often include access to Chinese‑made AI platforms, digital tools, and RWE datasets, turning these into core parts of the package.
Risks and Balance
Despite the momentum, not all China‑origin assets will succeed. Some trials fail, and regulatory or geopolitical tensions can slow global approvals. Payers in Europe and the U.S. also remain cautious on pricing, which can cap long‑term returns.
Executive Takeaway
China is no longer just a market—it’s now a global innovation engine for biotech licensing. For 2026, the key message is clear: anyone serious about access to next‑generation drugs must pay close attention to China‑sourced assets, pipelines, and partnerships, because the center of gravity in biopharma licensing has decisively shifted east.
By